Urethral cancer natural history, complications, and prognosis: Difference between revisions
Jump to navigation
Jump to search
Shanshan Cen (talk | contribs) |
|||
| (16 intermediate revisions by 2 users not shown) | |||
| Line 1: | Line 1: | ||
__NOTOC__ | __NOTOC__ | ||
{{Urethral cancer}} | {{Urethral cancer}} | ||
{{CMG}} | {{CMG}};{{AE}}{{Vbe}} | ||
==Overview== | ==Overview== | ||
The prognosis of urethral cancer varies with the depth of invasion, anatomical location, size, and stage of [[tumor]]. Superficial tumors located in the distal [[urethra]] have the most favorable [[prognosis]]. | Common [[complications]] of urethral cancer include [[metastasis]], [[anemia]], [[hydronephrosis]], [[urethral stricture]], and [[urinary incontinence]]. The [[prognosis]] of [[urethral]] [[cancer]] varies with the depth of invasion, [[anatomical]] location, size, and stage of [[tumor]]. Superficial [[tumors]] located in the distal [[urethra]] have the most favorable [[prognosis]]. | ||
==Natural History== | |||
*The [[symptoms]] of Urethral cancer usually develop in the 6th and 7th decade of life, and start with [[symptoms]] such as [[hematuria]], difficulty [[urinating]] and [[dysuria]]. | |||
==Complications== | |||
* Common [[complications]] of [[urethral]] [[cancer]] include: | |||
:* [[Anemia]] | |||
:* [[Hydronephrosis]] | |||
:* [[Urethral stricture]] | |||
:* [[Urinary incontinence]] | |||
:*[[Urinary system|Urinary]] [[retention]] | |||
:*[[Ureteral]] [[obstruction]] | |||
:*[[Lymphadenopathy]] in the [[groin]] and [[vaginal]] area | |||
==Prognosis== | ==Prognosis== | ||
* The prognosis of urethral cancer depends on the following factors:<ref name="cancergov"> National Cancer Institute. Physician Data Query Database 2015. http://www.cancer.gov/publications/pdq </ref> | * The [[prognosis]] of [[Urethral cancer|urethral]] [[cancer]] depends on the following factors:<ref name="cancergov">National Cancer Institute. Physician Data Query Database 2015. http://www.cancer.gov/publications/pdq </ref> | ||
:* Anatomical location | :* [[Anatomical]] location | ||
:* Size | :* [[Size consistency|Size]] | ||
:* Stage | :* [[Stage fright|Stage]] | ||
:* Depth of invasion | :* Depth of invasion | ||
* Superficial [[tumors]] located in the distal [[urethra]] of both the female and male are generally curable. However, deeply invasive lesions are rarely curable by any combination of therapies. | * Superficial [[tumors]] located in the [[distal]] [[urethra]] of both the [[female]] and [[male]] are generally curable. However, deeply invasive [[lesions]] are rarely curable by any combination of [[Therapies for multiple sclerosis|therapies]]. | ||
* In men, the [[prognosis]] of [[tumors]] in the distal (pendulous) [[urethra]] is better than for [[tumors]] of the proximal (bulbomembranous) and [[prostatic urethra]], which tend to present at more advanced stages. | * In men, the [[prognosis]] of [[tumors]] in the distal (pendulous) [[urethra]] is better than for [[tumors]] of the [[proximal]] (bulbomembranous) and [[prostatic urethra]], which tend to present at more advanced [[Stages of human development|stages]]. | ||
* Distal urethral [[tumors]] tend to occur at earlier stages in women, and they appear to have a better [[prognosis]] than proximal [[tumors]]. | * [[Distal]] [[urethral]] [[tumors]] tend to occur at earlier stages in [[Women's College Hospital|women]], and they appear to have a better [[prognosis]] than [[proximal]] [[tumors]]. | ||
* Lesions of the proximal or entire length of the [[urethra]] are usually associated with invasion and a high incidence of pelvic nodal [[metastases]] with 5-year survival rates ranging from 10% to 20%. | * [[Lesions]] of the [[proximal]] or entire length of the [[urethra]] are usually associated with invasion and a high [[incidence]] of [[pelvic]] [[Nodal (protein)|nodal]] [[metastases]] with 5-year survival rates ranging from 10% to 20%. | ||
==References== | ==References== | ||
Latest revision as of 16:59, 22 January 2019
|
Urethral cancer Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Urethral cancer natural history, complications, and prognosis On the Web |
|
American Roentgen Ray Society Images of Urethral cancer natural history, complications, and prognosis |
|
FDA on Urethral cancer natural history, complications, and prognosis |
|
CDC on Urethral cancer natural history, complications, and prognosis |
|
Urethral cancer natural history, complications, and prognosis in the news |
|
Blogs on Urethral cancer natural history, complications, and prognosis |
|
Risk calculators and risk factors for Urethral cancer natural history, complications, and prognosis |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1];Associate Editor(s)-in-Chief: Vindhya BellamKonda, M.B.B.S [2]
Overview
Common complications of urethral cancer include metastasis, anemia, hydronephrosis, urethral stricture, and urinary incontinence. The prognosis of urethral cancer varies with the depth of invasion, anatomical location, size, and stage of tumor. Superficial tumors located in the distal urethra have the most favorable prognosis.
Natural History
- The symptoms of Urethral cancer usually develop in the 6th and 7th decade of life, and start with symptoms such as hematuria, difficulty urinating and dysuria.
Complications
- Common complications of urethral cancer include:
Prognosis
- Anatomical location
- Size
- Stage
- Depth of invasion
- Superficial tumors located in the distal urethra of both the female and male are generally curable. However, deeply invasive lesions are rarely curable by any combination of therapies.
- In men, the prognosis of tumors in the distal (pendulous) urethra is better than for tumors of the proximal (bulbomembranous) and prostatic urethra, which tend to present at more advanced stages.
- Distal urethral tumors tend to occur at earlier stages in women, and they appear to have a better prognosis than proximal tumors.
- Lesions of the proximal or entire length of the urethra are usually associated with invasion and a high incidence of pelvic nodal metastases with 5-year survival rates ranging from 10% to 20%.
References
- ↑ National Cancer Institute. Physician Data Query Database 2015. http://www.cancer.gov/publications/pdq